Corvus Pharmaceuticals, Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019. Corvus is a clinical-stage oncology biopharmaceutical company with no product sales or operating revenue. Financial statements are unaudited.
Financial results and position
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $9.419 million | $12.103 million; down $2.684 million |
| General and administrative expense | $2.886 million | $2.541 million; up $0.345 million |
| Total operating expenses / operating loss | $12.305 million | $14.644 million |
| Interest income and other expense, net | $0.662 million income | $0.343 million income |
| Net loss | $11.643 million | $14.301 million |
| Net loss per share, basic and diluted | $0.40 | $0.63 |
| Net cash used in operating activities | $8.990 million | $11.045 million |
At March 31, 2019, cash and cash equivalents were $38.976 million and marketable securities were $66.831 million, totaling approximately $105.8 million. Total assets were $112.309 million, total liabilities $11.612 million, and stockholders’ equity $100.697 million. Accumulated deficit was $182.116 million. The filing reports no material borrowings; lease liabilities were $3.769 million, including $0.792 million current and $2.977 million long-term. Operating lease payments remaining for 2019–2022 totaled $4.563 million before imputed interest.
No meaningful gross or operating margin is reported because the company had no revenue. Cash and cash equivalents decreased by $0.220 million during the quarter; investing activities provided $8.769 million, primarily from net maturities of marketable securities, and financing provided $0.001 million. No material capital expenditures were reported.
Material changes versus Q1 2018
- Net loss narrowed by $2.658 million, reflecting lower R&D expense and higher investment income.
- R&D spending fell mainly because ciforadenant manufacturing and clinical trial costs declined, and CPI-006 manufacturing costs were lower. CPI-818 program costs rose as manufacturing and clinical work advanced.
- G&A expense increased $0.345 million, primarily due to personnel and professional services.
- Q1 2018 included $64.877 million in net proceeds from a follow-on offering; Q1 2019 had negligible financing proceeds. The 2018 comparison therefore benefited from a major equity raise that did not recur.
- The company adopted lease accounting Topic 842 on January 1, 2019, recognizing a right-of-use asset and lease liabilities.
Business, outlook and key risks
- Pipeline: Three of five oncology programs were in clinical trials. Ciforadenant, an A2A receptor antagonist, had enrolled more than 250 patients in its Phase 1/1b program. Management cited tolerability at studied doses and preliminary evidence of activity, particularly in renal cell and non-small cell lung cancers; these early findings are not proof of efficacy.
- CPI-006: The Phase 1/1b trial evaluates monotherapy and combinations with ciforadenant or pembrolizumab. Initial clinical data were expected at the ASCO annual meeting in June 2019. The company reported tolerability and changes in lymphocyte migration and activation, while noting limited patient numbers and follow-up.
- CPI-818: Patient enrollment in a Phase 1/1b trial for malignant T-cell lymphomas began in April 2019; initial data were anticipated in late 2019.
- Development outlook: Corvus planned to continue enrollment and development across its clinical programs and manufacturing work. It was considering a molecularly defined later-stage ciforadenant study in renal cell cancer around year-end 2019. These are plans, not assured milestones.
- Liquidity: Management said current cash, cash equivalents and marketable securities should fund planned expenditures and obligations for at least 12 months from issuance of the statements. However, the company does not expect existing resources to fund its clinical programs through commercialization and expects to seek additional capital, potentially through equity, debt or collaborations.
- Risks: Corvus has no approved products, revenue, or internal manufacturing capability and expects continuing losses. Development depends on uncertain clinical outcomes, patient enrollment, regulatory approvals, third-party manufacturers and trial operators, and collaboration arrangements. Additional financing may dilute shareholders, impose debt obligations, or require rights to be shared. The company disclosed potentially serious adverse events in ciforadenant combination trials; CPI-006 safety experience was limited.
- Contingencies and controls: No material legal proceedings were reported. Potential licensing milestones and royalties are contingent and not recorded as liabilities. Management concluded disclosure controls were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting.
Most important facts for investors to verify
- Whether clinical updates support the preliminary ciforadenant findings and whether safety concerns emerge, especially with combination treatment.
- Whether CPI-006 and CPI-818 data, enrollment, and timelines meet management’s stated expectations.
- How quickly cash and marketable securities are consumed relative to the stated 12-month liquidity outlook, and when additional financing may be needed.
- Whether changes in program spending reflect planned development progress or trial and manufacturing delays; confirm future financing needs and potential dilution.
- Whether third-party manufacturing, collaboration, licensing, or regulatory developments alter program costs, rights, or timelines.